Advanced Oncotherapy PLC (AVO) Stock Rating Reaffirmed by Beaufort Securities

Advanced Oncotherapy PLC (LON:AVO)‘s stock had its “speculative buy” rating reaffirmed by equities researchers at Beaufort Securities in a research report issued on Monday.

Shares of Advanced Oncotherapy PLC (LON:AVO) opened at 118.77 on Monday. Advanced Oncotherapy PLC has a 12-month low of GBX 98.00 and a 12-month high of GBX 217.25. The company’s 50 day moving average price is GBX 113.55 and its 200 day moving average price is GBX 140.30. The firm’s market cap is GBX 67.38 million.

About Advanced Oncotherapy PLC

Advanced Oncotherapy Plc is a United Kingdom-based company. The Company is engaged in providing medical technology for cancer treatment and managing a health-related property. The Company operates in three business segments: Proton Therapy, Single Dose Intra-Operative Radiotherapy Treatment (SDIORT) and Healthcare related properties.

Receive News & Ratings for Advanced Oncotherapy PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Oncotherapy PLC and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.